We are the Michigan State University Cystic Fibrosis Center, the largest clinical CF care center in central Michigan. Since 1990, we have delivered state-of-the-art holistic clinical care to pediatric and adult CF patients, and providing comprehensive education to families and caregivers. We are a core cystic fibrosis center, fully accredited by the Cystic Fibrosis Foundation, and our program consistently ranks as one of the top-performing CF centers in the country*.
*Based on nutritional (BMI) and FEV1 data in our children.
Interval History Form
Our interval history form is now available to download if you would like to fill it out prior to your visit.
Artificial Tears Lubricant Eye Drops P. aeruginosa Contamination
On Feb. 2, 2023, Global Pharma Healthcare voluntarily recalled all lots of their Artificial Tears Lubricant Eye Drops, distributed by EzriCare, LLC and Delsam Pharma, due to possible contamination by Pseudomonas aeruginosa. More information can be found here.
Ryan Thomas
2021 CF Foundation Patient Registry Highlights Report
The year 2021 was the second year of the COVID-19 pandemic and the third year elexacaftor/tezacaftor/ivacaftor was available for people with CF. The 2021 Registry data reflect a
combination of factors that impacted the lives of people with CF during the year. The favorable trends in lung function, pulmonary exacerbations, infection rates, and survival that were observed in 2020 data continued in 2021. These are strong indicators that broad uptake of elexacaftor/tezacaftor/ivacaftor is contributing to better health outcomes
Some highlights:
Mean lung function is up 13% for 10 year olds, 24% for 18 year olds and 27% for 30 year olds.
Predicted survial has increased by 20 years since the year 2000.
Chronic pseudomonas infection has been reduced from 43% to 28%.
Over half of CF adults now have a job.
Pregancy rates have more than doubled.
CF exacerbations have been cut in half.
Lung transplants have been reduced by 2/3!
This news is all really amazing.
Ryan Thomas
COVID-19 Antiviral Paxlovid and CF
Nirmatrelvir/ritonavir (Paxlovid) is an oral treatment for COVID-19 recently authorized for patients aged 12 years or older who weigh at least 88 pounds (40 kg). It is indicated for patients with mild to moderate COVID-19 who are at high risk of developing severe disease. This includes people with CF. There are expected interactions with cystic fibrosis transmembrane conductance regulator modulators (Trikafta, Kalydeco, Orkambi, Symdeco) and this medication whcih can lead to increased levels of the modulator in people. We strongly encourage you to call the CF Center about dose adjustments for your modulator and all other medications in the chronic treatment regimen if you need to use Paxlovid.
MSU, Spectrum Health partner on over $2M NIH gene therapy study for cystic fibrosis
A Michigan State University College of Human Medicine researcher has been awarded a federal grant to study a gene therapy treatment for cystic fibrosis, a potential cure for CF. The grant from the National Institutes of Health will allow a team of researchers led by Xiaopeng Li, PhD, an associate professor in the Department of Pediatrics and Human Development, to study how CFTR gene (the causal gene for cystic fibrosis) mutations in the small airways in the lungs of cystic fibrosis patients lead to life-threatening infections. Li will lead a team that includes College of Human Medicine researchers Jeremy Prokop, PhD and Christopher Waters, PhD. The team also includes four pulmonologists – Ryan Thomas, MD - from MSU College of Human Medicine and Reda Girgis, MD, Susan Millard, MD, and John Schuen, MD – from Spectrum Health and Helen DeVos Children’s Hospital Cystic Fibrosis Center.
More information below: